08:00 , Mar 5, 2001 |  BC Week In Review  |  Company News

Immunex management update

Immunex Corp. (IMNX), Seattle, Wash.   Business: Biopharmaceuticals   Hired: Efi Cohen-Arazi as SVP of supply operations, formerly general manager at an Ares- Serono S.A. manufacturing facility; and Michael Aguiar as VP of finance, formerly...
08:00 , Jan 16, 2001 |  BC Week In Review  |  Company News

Epicyte management update

Epicyte Pharmaceutical Inc., San Diego, Calif.   Business: Biomanufacturing, Antibodies   Hired: Christopher Clement as CEO, formerly SVP and chief marketing officer at Ares-Serono Group  ...
08:00 , Nov 28, 2000 |  BC Extra  |  Clinical News

Biogen reports Avonex dose comparison data

BGEN said that in a European study of 802 relapsing multiple sclerosis (MS) patients receiving either 30 or 60 ug of its Avonex interferon beta-1a once weekly, both doses showed similar efficacy in reducing disability...
07:00 , Oct 2, 2000 |  BioCentury  |  Politics, Policy & Law

Born with 2 mouths

Rep. Bill Thomas, BIO's "Legislator of the Year", may have embarrassed the trade organization last week by proclaiming that the biotechnology industry has little influence on Capitol Hill. But the biotech CEOs in his audience...
07:00 , Jun 19, 2000 |  BioCentury  |  Strategy

ProLease scorecard

The cancellation of a drug formulation partnership between Alkermes Inc. and Johnson & Johnson Co. is a reminder that such deals are really experiments, and pharma companies often pursue multiple routes to the same end...
07:00 , May 8, 2000 |  BC Week In Review  |  Clinical News

Rebif: Phase III data; marketed in Europe

AREB presented previously reported 4-year follow-up data from its 560-patient international PRISMS trial showing that high dose Rebif is significantly superior to low dose therapy in reducing relapses and delaying disease progression (see BioCentury, March...
07:00 , May 8, 2000 |  BC Week In Review  |  Company News

Axonyx, Ares-Serono deal

AREB exercised its option to license exclusively AXYX's anti-amyloid peptide technology to develop compounds to treat Alzheimer's disease and other neurological disorders. Under the proposed license agreement, AXYX will receive up to $22.5 million in...
07:00 , May 4, 2000 |  BC Extra  |  Company News

Ares-Serono exercises Axonyx option

Under their pending deal, the pharma company exclusively licensed AXYX's anti-amyloid peptide technology to develop compounds to treat Alzheimer's disease and other neurological disorders. AXYX will receive up to $25 million in milestones and is...
07:00 , Apr 10, 2000 |  BC Week In Review  |  Clinical News

Serono Pharmaceutical Research Institute preclinical data

Serono researchers presented data showing that its beta sheet breaker inhibited and dissolved amyloid deposits when injected into the brains of rats, producing a partial recovery of damaged neuronal and astroglial cells. Ares- Serono International...
07:00 , Apr 3, 2000 |  BC Week In Review  |  Company News

CeNeS, Ares-Serono deal

CeNeS will use its prolonged release gels and injection drug delivery technology to generate a new formulation of an Ares-Serono fertility drug. CeNeS will receive research fees and has manufacturing rights. CeNeS Pharmaceuticals plc (LSE:CEN),...